Publications and Acknowledgments

Publications

Movement Disorders

(Parkinson’s disease, Huntington’s disease, Dystonia)  

Lewitt PA, Hauser RA, Pahwa R, et al., and SPAN-PD Study Investigators including Burdick DJ. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. Feb 2019; 18(2):145-154. doi: 10.1016/S1474-4422(18)30405-8.

Agarwal P. (2019) Treatment of Orthostatic Tremor. In: Reich S., Factor S. (eds) Therapy of Movement Disorders. Current Clinical Neurology. Humana, Cham. doi: https://doi.org/10.1007/978-3-319-97897-0_39

Healio.com. Moving More in Old Age May Protect Memory, Thinking https://www.healio.com/internal-medicine/neurology/news/online/%7B36d9a452-f72f-40c5-8d3e-ea7b97bf77cf%7D/moving-more-in-old-age-may-protect-memory-thinking

Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, Agarwal P, Hull KL, Lyons KE, Johnson R, Stempien MJ. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study) A Randomized Clinical Trial. JAMA Neurol. Published online June 12, 2017. doi:10.1001/jamaneurol.2017.0943

Costa-Mallen P., Gatenby C., Friend S., Maravilla K.R., HuS.C., Cain K.C., Agarwal P., Anzai Y. (2017). Brain Iron Concentrations in Regions of Interest and Relation with Serum Iron Levels in Parkinson Disease. Journal of Neurological Sciences, In-Press.
doi: http://www.sciencedirect.com/science/article/pii/S0022510X17302691 

Costa-Mallen P., Zabetian C.P., Hu S.C., Agarwal P., Yearout D., Checkoway H. (2016). Smoking and haptoglobin phenotype modulate serum ferritin and haptoglobin levels in Parkinson disease. J Neural Tranm. Published online June 27, 2016. DOI: 10.1007/s00702-016-1590-x.

Huntington Study Group FirstHD Investigators including Agarwal P. Effect of Deutetrabenazine on Chorea Among Patients with Huntington Disease: A Randomized Clinical Trial. JAMA. 2016;316(1):40-50. doi:10.1001/jama.2016.8655. http://jama.jamanetwork.com/article.aspx?articleid=2532012 

LeDoux, M. S., Vemula, S. R., Xiao, J., Thompson, M. M., Perlmutter, J.S., Wright, L. J., ... Agarwal, P., on behalf of the Dystonia Coalition Investigators, Dystonia Genetic Consortium (2016). Clinical and genetic features of cervical dystonia in a large multicenter cohort. Neurology Genetics, 2(3), e69. http://dx.doi.org/10.1212/NXG.0000000000000069 

Costa-Mallen P., Zabetian C.P., Agarwal P., Hu S.C., Yearout D., Samii A. … Checkoway H. (2015). Haptoglobin phenotype modifies serum iron levels and the effect of smoking on Parkinson disease risk. Parkinsonism Relat Disord, 21(9): 1087-92. http://www.prd-journal.com/article/S1353-8020(15)00291-6/pdf 

Huntington Study Group Reach2HD Investigators including P. Agarwal. Safety, tolerability, and efficacy of PBT2 in Huntington’s disease: a phase 2, randomized, double-blind, placebo-controlled trial. Published online November 14, 2014. www.thelancet.com/neurology

Agarwal, P., & Zehnder, R. J. (2014). Foot drop. In A. B. Ettinger & D. M. Weisbrot (Eds.), Neurologic differential diagnosis: a case-based approach (pp. 178-181). Cambridge: Cambridge University Press.
http://www.cambridge.org/us/academic/subjects/medicine/neurology-and-clinical-neuroscience/neurologic-differential-diagnosis-case-based-approach

Burdick D.J., Griffith A., Agarwal P. (2014). A case of tremor in klinefelter syndrome worsened by testosterone administration. Twenty Eighth Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson Disease and Other Movement Disorders, 29(10), e2. http://onlinelibrary.wiley.com/doi/10.1002/mds.25967/citedby

Swanson, C. R., Li, K., Unger, T. L., Gallagher, M. D., Van Deerlin, V. M., Agarwal, P., … Chen-Plotkin, A. S. (2014), Lower plasma Apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype. Mov. Disord.. doi: 10.1002/mds.26022
http://www.ncbi.nlm.nih.gov/pubmed/25227208

The Parkinson Study Group QE3 Investigators. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014;71(5):543-552. doi:10.1001/jamaneurol.2014.131. http://archneur.jamanetwork.com/article.aspx?articleid=1851409  

Sanders K and Burdick DJ. Huntington’s Disease Case Study. Physician’s Field Guide to Neuropsychology: Collaboration through Case Example, ch. 19. Springer Nature (2019): New York, NY.

Agarwal P, Ray S, Burdick D, Griffith A, and Madan A. Efficacy and safety of ADS-5102 (amantadine) extended-release capsules for treating levodopa-induced dyskinesia. Expert Opinion on Orphan Drugs. Published Online October 2018 at https://doi.org/10.1080/21678707.2018.1525532

Kim HM, Leverenz JB, Burdick DJ, Srivatsal S, Pate J, Hu S-C, Millard SP, Davis MY, Samii A, and Zabetian CP. Diagnostic validation for participants in the Washington State Parkinson Disease Registry. Parkinson’s Disease. Published online November 2018 at https://doi.org/10.1155/2018/3719578

Madan A, Ray S, Burdick D, and Agarwal P. Management of lower urinary tract symptoms in Parkinson’s disease in the neurology clinic. International Journal of Neuroscience. December 2017; 127(12): 1136-1149.

Burdick DJ, Griffith A, and Agarwal P. A case of tremor in Klinefelter syndrome worsened by testosterone administration. Parkinsonism and Related Disorders. April 2015; 21(4):419.

Burdick DJ, Cholerton B, Watson GS, Siderowf A, Trojanowski JQ, Weintraub D, Ritz B, Rhodes SL, Rausch R, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Srivatsal S, Edwards KL, Montine TJ, Zabetian CP, and Leverenz JB. People with Parkinson disease and normal MMSE score have a broad range of cognitive performance. Movement Disorders. Sept 2014; 29(10):1258-1264.

Burdick DJ and Leverenz JB. Parkinson’s disease: pathology, anatomy, and behavior. Neuropsychiatric & Cognitive Changes in Parkinson’s Disease & Related Movement Disorders, ch. 2. Cambridge University Press (2013): Cambridge, UK.

Burdick DJ, Griffith A, and Agarwal P. Mydriasis in a Parkinson Disease Patient on Low-Dose Carbidopa/Levodopa. Movement Disorders. March 2013; 28(3): 295.


Multiple Sclerosis

Jeffrey A Cohen, Samuel F Hunter, Theodore R Brown, Mark Gudesblatt, Ben W Thrower, Lily Llorens, Cindy J Souza-Prien, April E Ruby, David N Chernoff and Rajiv Patni (2018) Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo­ controlled, phase 2 trial.
https://journals.sagepub.com/doi/10.1177/1352458518754716

Brown T.R. & Simnad, V.I. (2017). A Topical Adhesive Containing Anesthetic and Heating Components to Reduce Injection Pain with Subcutaneous Multiple Sclerosis Medications. International Journal of MS Care: March/April 2017, Vol. 19, No. 2, pp. 85-90. doi: http://dx.doi.org/10.7224/1537-2073.2015-099 

Brown T.R. & Simnad, V.I. (2016). Pilot Study of a Topical Adhesive Containing Anesthetic and Heating Components to Reduce Injection Pain with Subcutaneous Multiple Sclerosis Medications. International Journal of MS Care, In-Press. http://dx.doi.org/10.7224/1537-2073.2015-099

Brown T.R. & Simnad, V.I. (2016). A Randomized Crossover Trial of Dalfampridine Extended Release for Effect on Ambulatory Activity in People with Multiple Sclerosis. International Journal of MS Care: July/August 2016, 18(4), 170-176. http://ijmsc.org/doi/pdf/10.7224/1537-2073.2015-035

Brown T.R., Slee A. (2015). A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis. International Journal of MS Care, 17(2), 83-89. http://ijmsc.org/doi/pdf/10.7224/1537-2073.2014-001

Brown T. R., Simnad V. I., & Slee A. E. (2013). A study of topical diclofenac for glatiramer acetate injection reactions. Fifth Cooperative Meeting of CMSC and ACTRIMS. International Journal of MS Care, 15(S3), 41. http://ijmsc.org/doi/pdf/10.7224/1537-2073-15.S3.1

Brown T. R., Slee A. E. (2013). A randomized, placebo-controlled study of duloxetine for pain in multiple sclerosis. Fifth Cooperative Meeting of CMSC and ACTRIMS. International Journal of MS Care, 15(S3), 47. http://ijmsc.org/doi/pdf/10.7224/1537-2073-15.S3.1

Mohr D. C., Lovera J., Brown T. R. , et al. A randomized trial of stress management for the prevention of new brain lesions in MS. Neurology. 2012 Jul 31;79(5):412-9. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405245/pdf/znl412.pdf

Brown TR, Simnad VI. Development and validation of a myometric test of strength in lower extremities for multiple sclerosis patients using handheld dynamometer. Consortium of MS Centers Annual Meeting. 2014 (oral presentation # RH01). Int J MS Care 2014 Volume 16, Supplement 3, 7.

Goodman AD, Brown TR, et al. A Pooled Analysis of Two Phase 3 Clinical Trials of Dalfampridine in Patients with Multiple Sclerosis. Int J MS Care 2014 16:153-60.  http://www.ijmsc.org/doi/pdf/10.7224/1537-2073.2013-023                


Special Acknowledgments

MS Center

Ted Brown, MD, MPH

  • Dr. Brown is interviewed for Real World Health Care's blog about pain management in patients with multiple sclerosis (MS).
  • 2015 Herndon Award. Presented by the Consortium of Multiple Sclerosis Centers (CMSC), the Herndon Award for Outstanding IJMSC Article recognizes the best article published in the International Journal of MS Care during a given calendar year. Dr. Brown is the 2015 Herndon Award winner for his article "A Randomized Placebo-Controlled Trial of Duloxetine for Central Pain in Multiple Sclerosis," published in the March/April 2015 issue of IJMSC. 
  • Dr. Brown is featured on page 7 of the spring 2015 issue of the MS Connection newsletter.